Multiple genetic and molecular features have been associated with disease course in DLBCL, including translocation and/or overexpression of specific oncogenes (e.g., MYC, BCL2), mutational profiles, and transcriptome‐based classifiers such as the so‐called cell‐of‐origin (COO) and comprehensive consensus clustering (CCC) [1, 2, 3, 4, 5]. Here, BCL2 is linked to diffuse large B-cell lymphoma.